Compare State Street SPDR S&P Biotech ETF (XBI) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Xylem, Inc. — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.93, while Xylem, Inc. trades at $107.97 (market cap $25.41B). The key difference: Xylem, Inc. pays a 1.58% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Xylem, Inc. nearer its low. Which is the better fit depends on your goals.
| XBI | XYL | |
|---|---|---|
Sector | Broad Market / Factor | Industrials |
52-Week High | $169.55 | $152.95 |
52-Week Low | $93.43 | $105.69 |
Market Cap | — | $25.41B |
Enterprise Value | — | $27.18B |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
XYL trades at $108.81, up 2.95% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 10.59% net margin. Recent news highlights strategic acquisitions, a new CFO appointment, and a dividend declaration, supporting growth in water technology sectors. The stock shows resilience with revenue growth from $5.5B in 2022 to $9.04B in 2025, though it faces near-term resistance.
Outlook is cautiously optimistic with a consensus price target of $152.29 implying 40% upside, driven by margin expansion and AI-driven demand. Risks include execution of acquisitions and market volatility, but analyst sentiment leans buy/hold with low sell ratings. The stock presents a value opportunity for long-term investors focused on sustainable water solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
